Cue Biopharma, Inc. (CUE) Financial Statements (2023 and earlier)

Company Profile

Business Address 40 GUEST STREET
BOSTON, MA 02135
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:76,28964,40084,90059,41039,213
Cash and cash equivalents51,61464,37174,86644,29020,800
Short-term investments24,675 10,00315,12018,413
Other undisclosed cash, cash equivalents, and short-term investments  2931 0
Restricted cash and investments     50
Receivables573,1431,417755 
Other undisclosed current assets8419261,2108601,347
Total current assets:77,18768,46887,52761,02540,610
Noncurrent Assets
Operating lease, right-of-use asset9,2039,8106,7745,337
Property, plant and equipment1,4992,1122,1081,8472,781
Deposits noncurrent assets3,1162,7212,5722,5721,013
Restricted cash and investments150150150150150
Other noncurrent assets128140402674809
Total noncurrent assets:14,09614,93312,00610,5804,753
TOTAL ASSETS:91,28383,40199,53471,60545,363
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,2857,2114,8583,1103,823
Accounts payable2,7312,5912,0708832,035
Accrued liabilities3,5544,6202,7872,2271,788
Debt2,074  4,448 
Deferred rent credit     381
Other undisclosed current liabilities3,1895,57711,4584,0972,012
Total current liabilities:11,54912,78816,31611,6556,217
Noncurrent Liabilities
Long-term debt and lease obligation8,0355,1212,3691,348 
Long-term debt, excluding current maturities8,035    
Liabilities, other than long-term debt6,018    
Operating lease, liability6,0185,1212,3691,348
Other undisclosed noncurrent liabilities (5,121)(431)4,0185,175
Total noncurrent liabilities:14,0525,1214,3065,3665,175
Total liabilities:25,60117,90920,62217,02111,392
Equity
Equity, attributable to parent65,68365,49278,91154,58433,971
Common stock4332302721
Additional paid in capital316,192262,906232,159163,068105,763
Accumulated other comprehensive income (loss)(96) 7(10)(11)
Accumulated deficit(250,457)(197,446)(153,285)(108,500)(71,801)
Total equity:65,68365,49278,91154,58433,971
TOTAL LIABILITIES AND EQUITY:91,28383,40199,53471,60545,363

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues1,24514,9413,1543,4581,143
Operating lease, lease income277   
Gross profit:1,24514,9413,1543,4581,143
Operating expenses(54,470)(58,653)(48,197)(40,228)(39,839)
Operating loss:(53,225)(43,712)(45,043)(36,769)(38,697)
Nonoperating income21446464483541
Other nonoperating income    64165
Interest and debt expense(626)    
Loss from continuing operations before equity method investments, income taxes:(53,636)(43,666)(44,579)(36,286)(38,155)
Other undisclosed income from continuing operations before income taxes626    
Loss from continuing operations before income taxes:(53,010)(43,666)(44,579)(36,286)(38,155)
Income tax expense  (495)(206)(413)(825)
Loss from continuing operations:(53,010)(44,161)(44,785)(36,699)(38,980)
Loss before gain (loss) on sale of properties:(44,161)(44,785)(36,699)(38,980)
Other undisclosed net loss     
Net loss:(53,010)(44,161)(44,785)(36,699)(38,980)
Other undisclosed net income attributable to parent     
Net loss available to common stockholders, diluted:(53,010)(44,161)(44,785)(36,699)(38,980)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(53,010)(44,161)(44,785)(36,699)(38,980)
Other comprehensive income (loss)(96)(7)171 
Comprehensive loss:(53,106)(44,168)(44,767)(36,698)(38,980)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (11)
Comprehensive loss, net of tax, attributable to parent:(53,106)(44,168)(44,767)(36,698)(38,991)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: